Standout Papers
- Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies (2002)
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study (2017)
- Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy (2017)
Immediate Impact
5 by Nobel laureates 17 from Science/Nature 61 standout
Citing Papers
Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Tumour vasculature at single-cell resolution
2024 StandoutNature
Works of Thomas E. Stinchcombe being referenced
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
2017 Standout
Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
2012
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Thomas E. Stinchcombe | 3619 | 3751 | 806 | 1698 | 212 | 6.7k | |
| Wilfried Eberhardt | 5193 | 4130 | 873 | 1622 | 236 | 7.5k | |
| Otilia Dalesio | 3819 | 4373 | 1040 | 1472 | 103 | 7.9k | |
| Y Ariyoshi | 2783 | 3150 | 424 | 1940 | 125 | 5.4k | |
| Philip Bonomi | 4349 | 4803 | 961 | 2075 | 240 | 7.8k | |
| Mark Vincent | 3660 | 3695 | 708 | 1495 | 166 | 6.3k | |
| Michael L. Cher | 2462 | 1931 | 1591 | 1837 | 161 | 5.4k | |
| Masahiko Higashiyama | 3495 | 2103 | 936 | 1485 | 201 | 6.1k | |
| A. Dimitrios Colevas | 2030 | 3289 | 567 | 1572 | 189 | 7.4k | |
| Denis Soulières | 3211 | 3820 | 913 | 1861 | 253 | 7.2k | |
| Edward S. Kim | 5186 | 5109 | 1863 | 2856 | 211 | 9.5k |
All Works
Login with ORCID to disown or claim papers
Loading papers...